Eli Lilly and Company $LLY Shares Bought by Westwood Wealth Management

Westwood Wealth Management boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 129.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 954 shares of the company’s stock after acquiring an additional 539 shares during the quarter. Westwood Wealth Management’s holdings in Eli Lilly and Company were worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in LLY. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. grew its stake in shares of Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after purchasing an additional 10 shares during the last quarter. Bridgewater Advisors Inc. grew its stake in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after purchasing an additional 11 shares during the last quarter. Manske Wealth Management grew its stake in shares of Eli Lilly and Company by 2.5% in the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after purchasing an additional 11 shares during the last quarter. Finally, Guardian Partners Inc. grew its stake in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock valued at $3,302,000 after purchasing an additional 12 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Lilly’s oral weight‑loss pill Foundayo and bullish coverage pointing to multi‑billion dollar sales potential, supporting longer‑term revenue upside. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: Management says Lilly is ready to scale production of its new oral GLP‑1 and a new $6.5B Houston plant will manufacture the drug — alleviates supply concerns and supports faster commercialization. CEO Says Company Ready to Scale Production
• Positive Sentiment: Analysts have nudged price targets higher and some research houses continue to highlight Lilly’s path to very large market cap gains driven by GLP‑1 dominance and AI‑enabled R&D, supporting a favorable long‑term thesis. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly extended its collaboration with AC Immune on next‑generation Tau aggregation inhibitors for Alzheimer’s (IND‑enabling studies planned in 2026), diversifying R&D beyond obesity/diabetes but with longer timelines for material commercial impact. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Novo Nordisk launched a high‑dose Wegovy (7.2 mg) priced below Lilly’s competing GLP‑1 formulations — the new Wegovy HD undercuts Lilly on retail/cash price and could pressure market share and pricing power in the obesity category. A high dose of Wegovy will cost $50 less than Zepbound
• Negative Sentiment: An analyst downgrade was reported, and associated headlines note shares trading lower on the analyst callout — adding short‑term selling pressure despite the approval news. Eli Lilly Trading Down 1% on Analyst Downgrade
• Negative Sentiment: Market coverage highlighted that shares dipped after Foundayo’s approval due to intensified competition and patient/side‑effect considerations, reflecting investor concern about adoption dynamics and reimbursement. Stock Dips Following FDA Approval

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $930.08 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm’s fifty day moving average price is $988.75 and its 200 day moving average price is $973.25. The company has a market capitalization of $878.76 billion, a price-to-earnings ratio of 40.53, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the business earned $5.32 EPS. The business’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 target price on the stock. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.